Brought to you by 
Aposense nets $15mm in IPO on TASE
06 Dec 2010
Executive Summary
Aposense Ltd. (drug candidates and diagnostics targeting apoptosis) netted $15mm (NIS58.1mm) in its initial public offering on the Tel Aviv Stock Exchange. The company sold 2.03mm ordinary shares at $8.12. It also issued 507.3k Series 1 warrants and 1mm Series 2 warrants.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Radiopharmaceuticals, Contrast Agents
-
Medical Devices
-
Diagnostic Imaging Equipment & Supplies
- Molecular Imaging
-
Diagnostic Imaging Equipment & Supplies
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Nanotechnology, Chips, etc.
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Aposense nets $15mm in IPO on TASE
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice